Devin B Tesar
Overview
Explore the profile of Devin B Tesar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schwinghamer K, Kopec B, Ayewoh E, Tao X, Sadekar S, Sreedhara A, et al.
Mol Pharm
. 2024 Jul;
21(9):4416-4429.
PMID: 39058284
Monoclonal antibodies (mAbs) have high binding specificity and affinity, making them attractive for treating brain diseases. However, their effectiveness is limited by poor blood-brain barrier (BBB) penetration and rapid central...
2.
Schwinghamer K, Line S, Tesar D, Miller D, Sreedhara A, Siahaan T
Mol Pharm
. 2024 Feb;
21(4):1639-1652.
PMID: 38395041
Monoclonal antibodies (mAbs) possess favorable pharmacokinetic properties, high binding specificity and affinity, and minimal off-target effects, making them promising therapeutic agents for central nervous system (CNS) disorders. However, their development...
3.
Holz E, Darwish M, Tesar D, Shatz-Binder W
Pharmaceutics
. 2023 Feb;
15(2).
PMID: 36839922
Over the past few decades, the complexity of molecular entities being advanced for therapeutic purposes has continued to evolve. A main propellent fueling innovation is the perpetual mandate within the...
4.
Kelley R, Tesar D, Wang Y, Agard N, Holder P, Chan J, et al.
Mol Pharm
. 2022 Apr;
19(5):1540-1547.
PMID: 35393854
Treatment of age-related macular degeneration (AMD) with anti-vascular endothelial growth factor (VEGF) biologic agents has been shown to restore and maintain visual acuity for many patients afflicted with wet AMD....
5.
Mehta S, Kelley R, Tesar D
Drug Discov Today
. 2019 Jun;
24(8):1440-1445.
PMID: 31202674
Long-acting delivery (LAD) of ocular therapeutics has potential to improve the standard of care for ocular diseases, such as age-related macular degeneration (AMD), by increasing patient compliance and reducing overall...
6.
Yip V, Palma E, Tesar D, Mundo E, Bumbaca D, Torres E, et al.
MAbs
. 2014 Feb;
6(3):689-96.
PMID: 24572100
The neonatal Fc receptor (FcRn) plays an important and well-known role in antibody recycling in endothelial and hematopoietic cells and thus it influences the systemic pharmacokinetics (PK) of immunoglobulin G...
7.
Zheng Y, Tesar D, Benincosa L, Birnbock H, Boswell C, Bumbaca D, et al.
MAbs
. 2012 Mar;
4(2):243-55.
PMID: 22453096
Subcutaneous (SC) delivery is a common route of administration for therapeutic monoclonal antibodies (mAbs) with pharmacokinetic (PK)/pharmacodynamic (PD) properties requiring long-term or frequent drug administration. An ideal in vivo preclinical...
8.
Bai Y, Ye L, Tesar D, Song H, Zhao D, Bjorkman P, et al.
Proc Natl Acad Sci U S A
. 2011 Nov;
108(45):18406-11.
PMID: 22042859
IgG was traditionally thought to neutralize virions by blocking their attachment to or penetration into mucosal epithelial cells, a common site of exposure to viruses. However, we describe an intracellular...
9.
Boswell C, Tesar D, Mukhyala K, Theil F, Fielder P, Khawli L
Bioconjug Chem
. 2010 Nov;
21(12):2153-63.
PMID: 21053952
Antibody pharmacokinetics and pharmacodynamics are often governed by biological processes such as binding to antigens and other cognate receptors. Emphasis must also be placed, however, on fundamental physicochemical properties that...
10.
Jerdeva G, Tesar D, Huey-Tubman K, Ladinsky M, Fraser S, Bjorkman P
Traffic
. 2010 Jun;
11(9):1205-20.
PMID: 20525015
Protein delivery across polarized epithelia is controlled by receptor-mediated transcytosis. Many studies have examined basolateral-to-apical trafficking of polymeric IgA (pIgA) by the polymeric immunoglobulin receptor (pIgR). Less is known about...